Resverlogix Corp. (RVXCF)

0.0410 -0.0001 (-0.12%) At close: 11:39AM EDT

Resverlogix Corp.

4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1
Canada
403-254-9252
https://www.resverlogix.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Donald J. McCaffrey	Co-Founder, Chairman, President, CEO & Secretary	365.55k	N/A	N/A
Mr. Aaron Bradley Cann C.A., CPA, CBV	Chief Financial Officer	203.91k	N/A	N/A
Dr. Ewelina Kulikowski Ph.D.	Chief Scientific Officer	180.9k	N/A	N/A
Dr. Michael Sweeney M.D.	Senior Vice President of Clinical Development	370.16k	N/A	1961
Sarah Zapotichny	Director of Investor Relations & Corporate Communications	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.

Corporate Governance

Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.